Funded Biotechnology Startups in Dallas
Dallas biotechnology funding in this dataset spans August 2020 through September 2025, with round sizes ranging from a $30K pre-seed for ClearSight Therape…
Dallas biotechnology funding in this dataset spans August 2020 through September 2025, with round sizes ranging from a $30K pre-seed for ClearSight Therapeutics to Instil Bio's $170M raise in 2020 and Colossal Biosciences' $120M Series C in September 2025. The concentration of therapeutics-oriented companies — including Taysha Gene Therapies ($75M, June 2024), ReCode Therapeutics ($15M, November 2024), ImmuneSensor Therapeutics ($10M, December 2022), and Secretome Therapeutics ($7M, February 2023) — points to a therapeutics-heavy composition within the Dallas biotech cluster.
Disclosed round stages are sparse across the ten entries: most carry a "Series Unknown" designation, leaving Colossal Biosciences as the only company with a confirmed labeled stage (Series C). Vaxxinity is the sole grant recipient in the set ($9M, April 2022). Funding cadence shows a dip to a single close in 2023, bookended by three rounds each in 2022 and 2024, suggesting deal flow returned to prior levels heading into 2025.
Most recent rounds
10 shownRelated listings
Frequently asked
What are the largest rounds among Dallas biotech companies in this dataset?
Instil Bio leads at $170M (August 2020), followed by Colossal Biosciences at $120M in a Series C closed September 2025, and Taysha Gene Therapies at $75M in June 2024. These three account for the bulk of capital raised across all ten rows.
How transparent is round-stage disclosure among these Dallas biotech fundings?
Stage disclosure is limited — eight of the ten entries are labeled 'Series Unknown' or carry no stage at all. Colossal Biosciences (Series C) and ClearSight Therapeutics (Pre-Seed) are the only two companies with a confirmed stage on record.
Are there any non-dilutive funding events in this data?
One grant appears: Vaxxinity received $9M in April 2022. All other rounds are equity or venture-style instruments, though the undisclosed stages make it difficult to determine exact structure for the majority.
How has funding activity in this segment shifted across the years shown?
The dataset spans August 2020 through September 2025. Three rounds closed in 2022, one in 2023, three in 2024, and two in 2025 through September. Activity in 2024–2025 is spread across a broader deal-size range — from ClearSight Therapeutics' $30K pre-seed to Colossal Biosciences' $120M Series C.
What is the deal-size range across these Dallas biotech companies?
Rounds range from $30K (ClearSight Therapeutics, September 2024) to $170M (Instil Bio, August 2020). Most of the remaining eight entries fall between $2M and $120M, with no strong clustering around a single stage tier given the prevalence of undisclosed round types.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.